Fezam, capsules 60 pcs

Fezam is a combination drug that improves cerebral blood flow and brain metabolism.

Piracetam is a nootropic drug. It has a positive effect on metabolic processes and cerebral circulation. Increases glucose utilization, improves metabolic processes, improves microcirculation in ischemic areas, and inhibits activated platelet aggregation. It has a protective effect in brain damage caused by hypoxia.

Cinnarizine is a calcium channel blocker with a pronounced effect on cerebral vessels. It improves cerebral circulation, increases tissue resistance to hypoxia. It reduces the excitability of the vestibular system.

The two components mutually potentiate each other. With regard to the effect of the drug on the CNS, the sedative effect of cinnarizine prevails. The toxicity of the combination does not exceed the toxicity of the individual components.
The therapeutic effect occurs after 1-6 hours.

Pharmacokinetics

Absorption
Quickly and completely absorbed from the gastrointestinal tract.
C_max cinnarizine in plasma is noted after 1-4 hours, piracetam – after 2-6 hours.

Distribution
High concentration of cinnarizine after 1-4 hours is noted in the liver, kidneys, heart, lungs, spleen and brain. Cinnarizine binds 91% to plasma proteins.

Piracetam is rapidly distributed to all vital organs. It crosses the blood-brain barrier and is concentrated mainly in the gray matter of the cerebral cortex and cerebellum and also in the nucleus caudatus (caudate nucleus), hippocampus (hippocampus), corpus medianum, geniculus lateralis and plexus choroidalis (choroidal plexus).

Elimination
Piracetam is excreted unchanged in the urine in about 30 hours. 60% of cinnarizine is excreted unchanged in the feces, the rest is excreted with the urine as metabolites in about 5 hours.

Indications

Stroke after-effects, Vertigo, Migraine, Tinnitus, Attention and memory disorders, Atherosclerosis, Concussion and other brain injuries, Circulatory disorders, Meniere’s disease, Learning disabilities, Prevention of heart attacks and strokes, Seasickness, Asthenia< ul

.

Active ingredient

Piracetam, Cinnarizin

Composition

1 capsule contains:

acting substances:

piracetam 400 mg,

cinnarizine 25 mg,

excipients:

lactose;

colloidal silicon dioxide;

magnesium stearate

capsule shell:

titanium dioxide;

gelatin.

How to take, the dosage

In adults, the drug is prescribed 1-2 caps. 3 times a day for 1-3 months depending on the severity of the disease.

Children from 5 years of age are prescribed 1-2 capsules 1-2 times a day.

Interaction

When concomitant use of Fezam may increase the effect of sedatives, tricyclic antidepressants, nootropic and hypotensive drugs, as well as ethanol.

When used concomitantly, vasodilators increase the effect of Fezam, and hypertensive agents decrease it.

Special Instructions

Since Fezam contains cinnarizine, the drug may cause a positive reaction in athletes during a doping test.
When using the drug it is possible to change the results of determination of radioactive iodine (dyes in the capsule shell contain iodine).
Fezam is the drug of choice in cases where the monotherapy with piracetam causes tensions and insomnia in a patient.

Impact on driving and operating machinery

The administration of Fezam in therapeutic doses is possible (if the underlying disease allows) when driving vehicles and operating machinery and equipment.

Contraindications

• Individual intolerance,
• Severe hepatic and/or renal dysfunction,
• pregnancy,
• breastfeeding period,
• children under 5 years of age.

With caution – Parkinson’s disease.

Side effects

Dermatological reactions: in some cases – rash, itching, photosensitization.

Pregnancy use

Fezam is contraindicated in pregnancy and lactation.

Similarities

Omaron, Combitropil